Shinya Taniguchi

Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial

Atsushi Nakajima, Mitsunori Seki, Shinya Taniguchi et al. · ˜The œLancet. Gastroenterology & hepatology · 2018 · 169 citations

Medicine, Pharmacology, Pharmacotherapy +11

Olmesartan Is an Angiotensin II Receptor Blocker with an Inhibitory Effect on Angiotensin-Converting Enzyme

Jun Agata, Nobuyuki Ura, Hideaki Yoshida et al. · Hypertension Research · 2006 · 134 citations · Full text

Pharmacy, Cardiology, Pharmacology +13

A Homologue ofN-Ethylmaleimide-sensitive Factor in the Malaria ParasitePlasmodium falciparum Is Exported and Localized in Vesicular Structures in the Cytoplasm of Infected Erythrocytes in the Brefeldin A-sensitive Pathway

Mitsuko Hayashi, Shinya Taniguchi, Hye-Sook Kim et al. · Journal of Biological Chemistry · 2001 · 72 citations · Full text

Life Sciences, Genetics, Molecular Biology +11

Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial

Atsushi Nakajima, Mitsunori Seki, Shinya Taniguchi · Journal of Gastroenterology · 2017 · 61 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

QT PRODACT: A Multi-site Study of In Vitro Action Potential Assays on 21 Compounds in Isolated Guinea-Pig Papillary Muscles

Seiji Hayashi, Yoshihide Kii, Mitsuyasu Tabo et al. · Journal of Pharmacological Sciences · 2005 · 46 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13